Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study
Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in...
Gespeichert in:
| Veröffentlicht in: | Oncology 2011-01, Vol.80 (3-4), p.238-246 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 246 |
|---|---|
| container_issue | 3-4 |
| container_start_page | 238 |
| container_title | Oncology |
| container_volume | 80 |
| creator | Bruzzone, M. Centurioni, M.G. Giglione, P. Gualco, M. Merlo, D.F. Miglietta, L. Cosso, M. Giannelli, F. Cristoforoni, P. Ferrarini, M. |
| description | Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt. Methods: Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m 2 on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8–12 for 6 courses. Results: Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued. Conclusions: The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen. |
| doi_str_mv | 10.1159/000328451 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_21734415</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2423306561</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-febd2930cb1e6a619009fcbd542385c3d84739346354f199ccef93846e4ade5a3</originalsourceid><addsrcrecordid>eNpd0d-L1DAQB_AgireePvguEgQRH6r51Tb17VjOc2HhFu98LtNk6uVs0zVJV-5P8b81y64r-BQSPnwnM0PIS84-cF42HxljUmhV8kdkwZWQBRNSPCaL_MwKobg6I89ivM-sLlX1lJwJXkuleLkgv2_QTN4Wa-eR3gaENKJP9JdLd3TlU4Ad-mmO9ApH4xJ0ewbe0usAA71M03aKziJ1nm4GSM7PY_EVo4sJcsqF3YE3mPUOggNPl_troJssc5X4iWY7DynSqadAN3cQka5W9CbN9uE5edLDEPHF8Twn3z5f3i6_FOvrq9XyYl0YWYlU9NhZ0UhmOo4VVLxhrOlNZ8s8B10aabWqZSNVJUvV86YxBvtGalWhAoslyHPy7pC7DdPPGWNqRxcNDgN4zJ23utZayFo1Wb75T95Pc_D5c63WklVClDyj9wdkwhRjwL7dBjdCeGg5a_fbak_byvb1MXDuRrQn-Xc9Gbw9AogGhj7k-bn4zylZMy3r7F4d3A8I3zGcwLHOHxPtpW4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>883062251</pqid></control><display><type>article</type><title>Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study</title><source>Karger Journals</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Bruzzone, M. ; Centurioni, M.G. ; Giglione, P. ; Gualco, M. ; Merlo, D.F. ; Miglietta, L. ; Cosso, M. ; Giannelli, F. ; Cristoforoni, P. ; Ferrarini, M.</creator><creatorcontrib>Bruzzone, M. ; Centurioni, M.G. ; Giglione, P. ; Gualco, M. ; Merlo, D.F. ; Miglietta, L. ; Cosso, M. ; Giannelli, F. ; Cristoforoni, P. ; Ferrarini, M.</creatorcontrib><description>Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt. Methods: Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m 2 on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8–12 for 6 courses. Results: Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued. Conclusions: The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen.</description><identifier>ISSN: 0030-2414</identifier><identifier>EISSN: 1423-0232</identifier><identifier>DOI: 10.1159/000328451</identifier><identifier>PMID: 21734415</identifier><language>eng</language><publisher>Basel, Switzerland: Karger</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; CA-125 Antigen - blood ; Chemotherapy ; Clinical Study ; Clinical trials ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; Drug resistance ; Drug Resistance, Neoplasm ; Etoposide - administration & dosage ; Female ; Female genital diseases ; Gynecology. Andrology. Obstetrics ; Humans ; Medical sciences ; Middle Aged ; Ovarian cancer ; Ovarian Neoplasms - blood ; Ovarian Neoplasms - drug therapy ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - surgery ; Platinum - therapeutic use ; Survival Analysis ; Treatment Outcome ; Tumors</subject><ispartof>Oncology, 2011-01, Vol.80 (3-4), p.238-246</ispartof><rights>2011 S. Karger AG, Basel</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 S. Karger AG, Basel.</rights><rights>Copyright (c) 2011 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c362t-febd2930cb1e6a619009fcbd542385c3d84739346354f199ccef93846e4ade5a3</citedby><cites>FETCH-LOGICAL-c362t-febd2930cb1e6a619009fcbd542385c3d84739346354f199ccef93846e4ade5a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,2423,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24370837$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21734415$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bruzzone, M.</creatorcontrib><creatorcontrib>Centurioni, M.G.</creatorcontrib><creatorcontrib>Giglione, P.</creatorcontrib><creatorcontrib>Gualco, M.</creatorcontrib><creatorcontrib>Merlo, D.F.</creatorcontrib><creatorcontrib>Miglietta, L.</creatorcontrib><creatorcontrib>Cosso, M.</creatorcontrib><creatorcontrib>Giannelli, F.</creatorcontrib><creatorcontrib>Cristoforoni, P.</creatorcontrib><creatorcontrib>Ferrarini, M.</creatorcontrib><title>Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study</title><title>Oncology</title><addtitle>Oncology</addtitle><description>Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt. Methods: Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m 2 on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8–12 for 6 courses. Results: Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued. Conclusions: The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>CA-125 Antigen - blood</subject><subject>Chemotherapy</subject><subject>Clinical Study</subject><subject>Clinical trials</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Drug resistance</subject><subject>Drug Resistance, Neoplasm</subject><subject>Etoposide - administration & dosage</subject><subject>Female</subject><subject>Female genital diseases</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - blood</subject><subject>Ovarian Neoplasms - drug therapy</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - surgery</subject><subject>Platinum - therapeutic use</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0030-2414</issn><issn>1423-0232</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0d-L1DAQB_AgireePvguEgQRH6r51Tb17VjOc2HhFu98LtNk6uVs0zVJV-5P8b81y64r-BQSPnwnM0PIS84-cF42HxljUmhV8kdkwZWQBRNSPCaL_MwKobg6I89ivM-sLlX1lJwJXkuleLkgv2_QTN4Wa-eR3gaENKJP9JdLd3TlU4Ad-mmO9ApH4xJ0ewbe0usAA71M03aKziJ1nm4GSM7PY_EVo4sJcsqF3YE3mPUOggNPl_troJssc5X4iWY7DynSqadAN3cQka5W9CbN9uE5edLDEPHF8Twn3z5f3i6_FOvrq9XyYl0YWYlU9NhZ0UhmOo4VVLxhrOlNZ8s8B10aabWqZSNVJUvV86YxBvtGalWhAoslyHPy7pC7DdPPGWNqRxcNDgN4zJ23utZayFo1Wb75T95Pc_D5c63WklVClDyj9wdkwhRjwL7dBjdCeGg5a_fbak_byvb1MXDuRrQn-Xc9Gbw9AogGhj7k-bn4zylZMy3r7F4d3A8I3zGcwLHOHxPtpW4</recordid><startdate>20110101</startdate><enddate>20110101</enddate><creator>Bruzzone, M.</creator><creator>Centurioni, M.G.</creator><creator>Giglione, P.</creator><creator>Gualco, M.</creator><creator>Merlo, D.F.</creator><creator>Miglietta, L.</creator><creator>Cosso, M.</creator><creator>Giannelli, F.</creator><creator>Cristoforoni, P.</creator><creator>Ferrarini, M.</creator><general>Karger</general><general>S. Karger AG</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20110101</creationdate><title>Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study</title><author>Bruzzone, M. ; Centurioni, M.G. ; Giglione, P. ; Gualco, M. ; Merlo, D.F. ; Miglietta, L. ; Cosso, M. ; Giannelli, F. ; Cristoforoni, P. ; Ferrarini, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-febd2930cb1e6a619009fcbd542385c3d84739346354f199ccef93846e4ade5a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>CA-125 Antigen - blood</topic><topic>Chemotherapy</topic><topic>Clinical Study</topic><topic>Clinical trials</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Drug resistance</topic><topic>Drug Resistance, Neoplasm</topic><topic>Etoposide - administration & dosage</topic><topic>Female</topic><topic>Female genital diseases</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - blood</topic><topic>Ovarian Neoplasms - drug therapy</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - surgery</topic><topic>Platinum - therapeutic use</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bruzzone, M.</creatorcontrib><creatorcontrib>Centurioni, M.G.</creatorcontrib><creatorcontrib>Giglione, P.</creatorcontrib><creatorcontrib>Gualco, M.</creatorcontrib><creatorcontrib>Merlo, D.F.</creatorcontrib><creatorcontrib>Miglietta, L.</creatorcontrib><creatorcontrib>Cosso, M.</creatorcontrib><creatorcontrib>Giannelli, F.</creatorcontrib><creatorcontrib>Cristoforoni, P.</creatorcontrib><creatorcontrib>Ferrarini, M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bruzzone, M.</au><au>Centurioni, M.G.</au><au>Giglione, P.</au><au>Gualco, M.</au><au>Merlo, D.F.</au><au>Miglietta, L.</au><au>Cosso, M.</au><au>Giannelli, F.</au><au>Cristoforoni, P.</au><au>Ferrarini, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study</atitle><jtitle>Oncology</jtitle><addtitle>Oncology</addtitle><date>2011-01-01</date><risdate>2011</risdate><volume>80</volume><issue>3-4</issue><spage>238</spage><epage>246</epage><pages>238-246</pages><issn>0030-2414</issn><eissn>1423-0232</eissn><abstract>Objective: The outcome of advanced ovarian cancer patients has not significantly improved since the introduction of platinum. One of the major reasons for this failure is the lack of an effective second-line treatment. In this phase II trial we tested the combination of gemcitabine and etoposide in 2 different groups of patients. Group 1 consisted of patients showing disease progression or relapse within 6 months of first-line platinum-based chemotherapy. Group 2 comprised heavily pretreated patients showing progression during the last chemotherapy attempt. Methods: Thirty-four patients were enrolled. Gemcitabine was administered at a dose of 1,000 mg/m 2 on days 1 and 8 and etoposide was administered orally at 100 mg/day on days 8–12 for 6 courses. Results: Eighteen patients (52.9%) had an objective response and the median duration of the response was 10.3 months. Our chemotherapy regimen showed a low toxicity and good patient compliance. In 5 patients the treatment had to be delayed and in only 2 patients it was discontinued. Conclusions: The combination of gemcitabine and oral etoposide seems to be a safe and effective second-line treatment for platinum-resistant ovarian cancer patients. Additional data on larger series are warranted to better define the activity of this combination regimen.</abstract><cop>Basel, Switzerland</cop><pub>Karger</pub><pmid>21734415</pmid><doi>10.1159/000328451</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0030-2414 |
| ispartof | Oncology, 2011-01, Vol.80 (3-4), p.238-246 |
| issn | 0030-2414 1423-0232 |
| language | eng |
| recordid | cdi_pubmed_primary_21734415 |
| source | Karger Journals; MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences CA-125 Antigen - blood Chemotherapy Clinical Study Clinical trials Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives Drug resistance Drug Resistance, Neoplasm Etoposide - administration & dosage Female Female genital diseases Gynecology. Andrology. Obstetrics Humans Medical sciences Middle Aged Ovarian cancer Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - pathology Ovarian Neoplasms - surgery Platinum - therapeutic use Survival Analysis Treatment Outcome Tumors |
| title | Second-Line Treatment with Intravenous Gemcitabine and Oral Etoposide in Platinum-Resistant Advanced Ovarian Cancer Patients: Results of a Phase II Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T03%3A54%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Second-Line%20Treatment%20with%20Intravenous%20Gemcitabine%20and%20Oral%20Etoposide%20in%20Platinum-Resistant%20Advanced%20Ovarian%20Cancer%20Patients:%20Results%20of%20a%20Phase%20II%20Study&rft.jtitle=Oncology&rft.au=Bruzzone,%20M.&rft.date=2011-01-01&rft.volume=80&rft.issue=3-4&rft.spage=238&rft.epage=246&rft.pages=238-246&rft.issn=0030-2414&rft.eissn=1423-0232&rft_id=info:doi/10.1159/000328451&rft_dat=%3Cproquest_pubme%3E2423306561%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=883062251&rft_id=info:pmid/21734415&rfr_iscdi=true |